In one paragraphArticle in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jinzhi WangNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.
Shuwen ZhengNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.
Ruzetuoheti YiminniyazeNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.ORCID https://orcid.org/0000-0002-9403-9613 Hanyu ZhengNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.
Shuai ZhangNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.
Han TianNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.
Yanhua KongNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.ORCID https://orcid.org/0000-0002-0024-0050 Wanmu XieNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.ORCID https://orcid.org/0000-0002-6686-3517 Zhenguo ZhaiNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China-Japan Friendship Hospital Beijing China.ORCID https://orcid.org/0000-0002-7096-8792 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Pulmonary hypertension (PH) is a severe complication of Takayasu arteritis (TAK) with pulmonary artery involvement (PAI), associated with poor prognosis. Serum uric acid (UA) has been linked to both TAK severity and PH in other settings, but its role specifically in TAK-PAI-associated PH remains unclear. This study aimed to investigate the relationship between serum UA and the presence and severity of PH in TAK patients with confirmed PAI. This cross-sectional study enrolled 90 consecutive TAK patients with PAI documented by CT pulmonary angiography. All patients underwent echocardiography; those with echocardiographic signs of PH underwent confirmatory right heart catheterization (RHC). PH was defined as mean pulmonary artery pressure > 20 mmHg with pulmonary artery wedge pressure ≤ 15 mmHg (2022 ESC/ERS criteria). Serum UA was measured at baseline. Multivariable logistic regression, subgroup analyses, and restricted cubic spline (RCS) were performed. Among 90 patients, 42 (46.7%) met the PH criteria. Patients with PH had significantly higher serum UA levels than those without PH (400.5 ± 140.8 vs. 305.2 ± 91.6 μmol/L,
Indexed as
cross‐sectional studypulmonary artery involvementpulmonary hypertensionTakayasu arteritisuric acid
Identifiers
PMID42746108
PMCPMC13575858
What OpenQuestion holds
Textmetadata
Read underepoch 390